These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 26271310)

  • 1. Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.
    Liu CS; Chau SA; Ruthirakuhan M; Lanctôt KL; Herrmann N
    CNS Drugs; 2015 Aug; 29(8):615-23. PubMed ID: 26271310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural and Synthetic Cannabinoids for Agitation and Aggression in Alzheimer's Disease: A Meta-Analysis.
    Ruthirakuhan M; Lanctôt KL; Vieira D; Herrmann N
    J Clin Psychiatry; 2019 Jan; 80(2):. PubMed ID: 30753761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological Management of Agitation and Aggression in Alzheimer's Disease: A Review of Current and Novel Treatments.
    Liu CS; Ruthirakuhan M; Chau SA; Herrmann N; Carvalho AF; Lanctôt KL
    Curr Alzheimer Res; 2016; 13(10):1134-44. PubMed ID: 27137221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review of Clinical Studies on the Effect of Psychoactive Cannabinoids in Psychiatric Conditions in Alzheimer Dementia.
    Paunescu H; Dima L; Ghita I; Coman L; Ifteni PI; Fulga I; Coman OA
    Am J Ther; 2020; 27(3):e249-e269. PubMed ID: 32118591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoids for Agitation in Alzheimer's Disease.
    Outen JD; Burhanullah MH; Vandrey R; Amjad H; Harper DG; Patrick RE; May RL; Agronin ME; Forester BP; Rosenberg PB
    Am J Geriatr Psychiatry; 2021 Dec; 29(12):1253-1263. PubMed ID: 33573996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease.
    Herrmann N; Gauthier S; Boneva N; Lemming OM;
    Int Psychogeriatr; 2013 Jun; 25(6):919-27. PubMed ID: 23472619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease.
    Herrmann N; Ruthirakuhan M; Gallagher D; Verhoeff NPLG; Kiss A; Black SE; Lanctôt KL
    Am J Geriatr Psychiatry; 2019 Nov; 27(11):1161-1173. PubMed ID: 31182351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the advancements in the treatment of agitation in Alzheimer's disease.
    Porsteinsson AP; Antonsdottir IM
    Expert Opin Pharmacother; 2017 Apr; 18(6):611-620. PubMed ID: 28300462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design.
    Devanand DP; Strickler JG; Huey ED; Crocco E; Forester BP; Husain MM; Vahia IV; Andrews H; Wall MM; Pelton GH
    Contemp Clin Trials; 2018 Aug; 71():33-39. PubMed ID: 29859917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
    Daiello LA
    Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer's Disease: Analyses from a Clinical Trial with Nabilone.
    Ruthirakuhan M; Herrmann N; Andreazza AC; Verhoeff NPLG; Gallagher D; Black SE; Kiss A; Lanctôt KL
    J Alzheimers Dis; 2019; 71(1):21-31. PubMed ID: 31322567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancements in the treatment of agitation in Alzheimer's disease.
    Antonsdottir IM; Smith J; Keltz M; Porsteinsson AP
    Expert Opin Pharmacother; 2015; 16(11):1649-56. PubMed ID: 26159445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agitation and aggression in people with Alzheimer's disease.
    Ballard C; Corbett A
    Curr Opin Psychiatry; 2013 May; 26(3):252-9. PubMed ID: 23528917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: Study protocol for a cross-over randomized controlled trial.
    Ruthirakuhan MT; Herrmann N; Gallagher D; Andreazza AC; Kiss A; Verhoeff NPLG; Black SE; Lanctôt KL
    Contemp Clin Trials Commun; 2019 Sep; 15():100385. PubMed ID: 31338476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia.
    Sommer OH; Aga O; Cvancarova M; Olsen IC; Selbaek G; Engedal K
    Dement Geriatr Cogn Disord; 2009; 27(2):155-63. PubMed ID: 19182483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia.
    Davies SJ; Burhan AM; Kim D; Gerretsen P; Graff-Guerrero A; Woo VL; Kumar S; Colman S; Pollock BG; Mulsant BH; Rajji TK
    J Psychopharmacol; 2018 May; 32(5):509-523. PubMed ID: 29338602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.
    Schneider LS; Frangakis C; Drye LT; Devanand DP; Marano CM; Mintzer J; Mulsant BH; Munro CA; Newell JA; Pawluczyk S; Pelton G; Pollock BG; Porsteinsson AP; Rabins PV; Rein L; Rosenberg PB; Shade D; Weintraub D; Yesavage J; Lyketsos CG;
    Am J Psychiatry; 2016 May; 173(5):465-72. PubMed ID: 26771737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.
    Cummings JL; Lyketsos CG; Peskind ER; Porsteinsson AP; Mintzer JE; Scharre DW; De La Gandara JE; Agronin M; Davis CS; Nguyen U; Shin P; Tariot PN; Siffert J
    JAMA; 2015 Sep 22-29; 314(12):1242-54. PubMed ID: 26393847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.